An overview of drugs in development that might improve cognitive symptoms (or might not):
# New Therapies Target NMDARs to Improve Schizophrenia Symptoms - 19 March 2025, Psychiatrist.com
Clinical relevance: Cognitive impairment in schizophrenia remains challenging, with standard antipsychotics often failing to improve cognitive symptoms.
- Researchers are investigating NMDAR hypofunction as a key factor in schizophrenia’s cognitive issues.
- D-serine and glycine have shown promise in improving symptoms but still face challenges.
- Novel approaches, including DAAO and GlyT1 inhibitors, are being explored to enhance NMDAR function and improve cognitive outcomes.